Alunbrig (brigatinib) approved in Europe for another type of lung cancer
Last updated: 01 November 2019
You can legally access new medicines, even if they are not approved in your country.
Learn more »Alunbrig (brigatinib) has been approved by the European Commission for the treatment of adult patients with ALK-positive non–small cell lung cancer (NSCLC) who were previously treated with another lung cancer medicine.
In a clinical trial, patients showed 56% positive response rate and survived for 34 months on average when treated with 180-mg dose of brigatinib. Jesús Gómez-Navarro, MD, vice president, Head of Oncology Clinical Research and Development, Takeda stated, “The European Commission’s decision to approve Alunbrig for patients with ALK-positive NSCLC is a significant advancement for European patients impacted by this life-threatening disease.”
For more information see the full article at Once Live.
